Affinity Asset Advisors’s Perspective Therapeutics CATX Stock Holding History

Affinity Asset Advisors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.2M	Buy	3,164,582 +2,864,582	+955%	+$12.1M	0.68%	39
2025 Q4	$825K	Hold	300,000	–	–	0.05%	88
2025 Q3	$1.03M	Sell	300,000 -750,000	-71%	-$2.73M	0.09%	85
2025 Q2	$3.61M	Sell	1,050,000 -1,174,196	-53%	-$3.1M	0.49%	48
2025 Q1	$4.74M	Buy	2,224,196 +924,196	+71%	+$2.77M	0.45%	45
2024 Q4	$4.15M	Buy	1,300,000 +800,000	+160%	+$6.53M	0.56%	40
2024 Q3	$6.67M	Sell	500,000 -50,000	-9%	-$665K	0.91%	37
2024 Q2	$5.48M	Buy	550,000 +40,000	+8%	+$578K	0.63%	42
2024 Q1	$6.07M	Buy	+510,000	New	+$4.35M	0.75%	39

Other funds holding CATX

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Affinity Asset Advisors's CATX Position: Q1 2026 in Review

Affinity Asset Advisors increased its Perspective Therapeutics (CATX) stake by 955% in Q1 2026, buying an estimated $12.1M and bringing the position to 3,164,582 shares worth $13.2M. The position accounts for 0.68% of the portfolio, ranked #39.

Affinity Asset Advisors first reported a position in CATX in Q1 2024 and has held it in 9 quarters since. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

Affinity Asset Advisors held 3,164,582 shares of Perspective Therapeutics worth $13.2M as of Q1 2026.
Affinity Asset Advisors bought 2,864,582 Perspective Therapeutics shares in Q1 2026, an estimated $12.1M.
Perspective Therapeutics made up 0.68% of Affinity Asset Advisors's portfolio in Q1 2026, its #39 holding.
Affinity Asset Advisors first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 9 quarters since.
138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.